Mabylon AG
Dimitri Bieli has extensive experience in molecular biology, holding various roles such as Executive Vice President, Head, and Research Scientist. Prior to their current position at Mabylon AG, Dimitri worked as a Postdoctoral Researcher at the University of Basel. Dimitri has also gained experience through internships and positions such as a Dachdecker and a Driver. Dimitri holds a Doctor of Philosophy (PhD) in Molekulargenetik, a Master of Science (MSc) in Entwicklungsbiologie und Embryologie, and a Bachelor of Science (BSc) in Molekularbiologie from the University of Basel.
This person is not in any teams
Mabylon AG
Mabylon AG, a private Swiss biotech company, is leading innovation in antibody-based treatments for severe allergies, inflammation, and neurological disorders. Our B-cell screening platform identifies natural human antibodies with high specificity and therapeutic potential. MY006, our first-in-class multispecific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.